DOI: 10.1038/sj.bjc.6600516. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

10.1038/sj.bjc.6600516

Crossref journal-article

Springer Science and Business Media LLC

British Journal of Cancer (297)

Bibliography

Schoemaker, N. E., van Kesteren, C., Rosing, H., Jansen, S., Swart, M., Lieverst, J., Fraier, D., Breda, M., Pellizzoni, C., Spinelli, R., Porro, M. G., Beijnen, J. H., Schellens, J. H. M., & ten Bokkel Huinink, W. W. (2002). A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. British Journal of Cancer, 87(6), 608â614.

Authors 14

N E Schoemaker (first)
C van Kesteren (additional)
H Rosing (additional)
S Jansen (additional)
M Swart (additional)
J Lieverst (additional)
D Fraier (additional)
M Breda (additional)
C Pellizzoni (additional)
R Spinelli (additional)
M Grazia Porro (additional)
J H Beijnen (additional)
J H M Schellens (additional)
W W ten Bokkel Huinink (additional)

References 21 Referenced 98

Caiolfa VR, Zamai M, Fiorino A, Frigerio E, Pellizzoni C, d'Argy R, Ghiglieri A, Castelli MG, Farao M, Pesenti E, Gigli M, Angelucci F, Suarato A (2000) Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 65: 105–119 (10.1016/S0168-3659(99)00243-6) / J Control Release by VR Caiolfa (2000)
Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245–259 (10.2165/00003088-199733040-00001) / Clin Pharmacokinet by GG Chabot (1997)
Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL (1998) Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethyulene glycol via a glycine linker. Cancer Chemother Pharmacol 42: 407–414 (10.1007/s002800050837) / Cancer Chemother Pharmacol by CD Conover (1998)
Conover CD, Greenwald RB, Pendri A, Sum K (1999) Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-cancer Drug Design 14: 499–506 / Anti-cancer Drug Design by CD Conover (1999)
Houghton PJ, Cheshire PJ, Hallman II JD, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumours. Cancer Chemother Pharmacol 36: 393–403 (10.1007/BF00686188) / Cancer Chemother Pharmacol by PJ Houghton (1995)
Kehrer DF, Soepenberg O, Loos WJ, Verweij J, Sparreboom A (2001) Modulation of camptothecin analogs in the treatment of cancer: a review. Anti-Cancer Drugs 12: 89–105 (10.1097/00001813-200102000-00002) / Anti-Cancer Drugs by DF Kehrer (2001)
Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher MJ, Caranfa FL, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1990) Synthesis of water soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98–107 (10.1021/jm00105a017) / J Med Chem by WD Kingsbury (1990)
Lott RS, Hayton WL (1978) Estimation of creatinine clearance from serum creatinine concentration. Drug Intel Clin Pharm 12: 140–150 / Drug Intel Clin Pharm by RS Lott (1978)
Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JHM, Schot M, Mandjes IAM, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH (2001) Phase I clinical study of PNU 166945, a novel water-soluble polymer conjugated prodrug of paclitaxel. Anticancer Drugs 12: 315–323 (10.1097/00001813-200104000-00003) / Anticancer Drugs by JM Meerum Terwogt (2001)
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Reports 56: 95–101 / Cancer Chemother Reports by CG Moertel (1972)
Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Reports 56: 515–521 / Cancer Chemother Reports by FM Muggia (1972)
NCI (1998) Guidelines for Reporting of Adverse Drug Reactions. National Cancer Institute, Division of Cancer Treatment, Bethesda, MD, USA
Rivory LP, Robert J (1995) Melcular cellular clinical aspects of the pharmacology of 20 (S)Camptothecin and its derivatives. Pharmac Ther 68: 269–296 (10.1016/0163-7258(95)02009-8) / Pharmac Ther by LP Rivory (1995)
Schoemaker NE, Frigerio E, Fraier D, Schellens JHM, Rosing H, Jansen S, Beijnen JH (2001) High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-Camptothecin) and free camptothecin in human plasma. J Chrom B 763: 173–183 (10.1016/S0378-4347(01)00391-7) / J Chrom B by NE Schoemaker (2001)
Seymour LW (1992) Passive tumor targetting of soluble macromolecules drug conjugates. Crit Rev Ther Drug Carrier Sys 9: 135–187 / Crit Rev Ther Drug Carrier Sys by LW Seymour (1992)
Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accellerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138–1147 (10.1093/jnci/89.15.1138) / J Natl Cancer Inst by R Simon (1997)
Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271–291 (10.1093/jnci/85.4.271) / J Natl Cancer Inst by WJ Slichenmyer (1993)
Traub SL, Johnson CE (1980) Comparison of methods of estimating creatinine clearance in children. Am J Hosp Pharm 37: 195–201 / Am J Hosp Pharm by SL Traub (1980)
Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J (1999) Phase I clinical and pharmacodynamic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents–drug-polymer conjugates. Clin Cancer Res 5: 83–94 / Clin Cancer Res by PA Vasey (1999)
Wall ME, Wani MC (1996) Camptothecin Discovery to clinic. Ann NY Ac Sc 803: 1–12 (10.1111/j.1749-6632.1996.tb26371.x) / Ann NY Ac Sc by ME Wall (1996)
WHO (1979) WHO handbook for Reporting Results of Cancer Treatment World Health Organization, Geneva, Switzerland

Dates

Type	When
Created	22 years, 11 months ago (Sept. 25, 2002, 6:58 a.m.)
Deposited	2 years, 3 months ago (May 18, 2023, 8:44 a.m.)
Indexed	5 months, 1 week ago (March 22, 2025, 4:37 a.m.)
Issued	23 years ago (Sept. 1, 2002)
Published	23 years ago (Sept. 1, 2002)
Published Online	23 years ago (Sept. 3, 2002)
Published Print	23 years ago (Sept. 1, 2002)

Funders 0

None

BibTeX

@article{Schoemaker_2002, title={A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin}, volume={87}, ISSN={1532-1827}, url={http://dx.doi.org/10.1038/sj.bjc.6600516}, DOI={10.1038/sj.bjc.6600516}, number={6}, journal={British Journal of Cancer}, publisher={Springer Science and Business Media LLC}, author={Schoemaker, N E and van Kesteren, C and Rosing, H and Jansen, S and Swart, M and Lieverst, J and Fraier, D and Breda, M and Pellizzoni, C and Spinelli, R and Porro, M Grazia and Beijnen, J H and Schellens, J H M and ten Bokkel Huinink, W W}, year={2002}, month=sep, pages={608–614} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        3,
        22
      ]
    ],
    "date-time": "2025-03-22T08:37:02Z",
    "timestamp": 1742632622362
  },
  "reference-count": 21,
  "publisher": "Springer Science and Business Media LLC",
  "issue": "6",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2002,
            9,
            1
          ]
        ],
        "date-time": "2002-09-01T00:00:00Z",
        "timestamp": 1030838400000
      },
      "content-version": "unspecified",
      "delay-in-days": 0,
      "URL": "http://www.springer.com/tdm"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2002,
        9
      ]
    ]
  },
  "DOI": "10.1038/sj.bjc.6600516",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2002,
        9,
        25
      ]
    ],
    "date-time": "2002-09-25T10:58:03Z",
    "timestamp": 1032951483000
  },
  "page": "608-614",
  "source": "Crossref",
  "is-referenced-by-count": 98,
  "title": "A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin",
  "prefix": "10.1038",
  "volume": "87",
  "author": [
    {
      "given": "N E",
      "family": "Schoemaker",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "C",
      "family": "van Kesteren",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "H",
      "family": "Rosing",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "S",
      "family": "Jansen",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "M",
      "family": "Swart",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "J",
      "family": "Lieverst",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "D",
      "family": "Fraier",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "M",
      "family": "Breda",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "C",
      "family": "Pellizzoni",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "R",
      "family": "Spinelli",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "M Grazia",
      "family": "Porro",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "J H",
      "family": "Beijnen",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "J H M",
      "family": "Schellens",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "W W",
      "family": "ten Bokkel Huinink",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "297",
  "published-online": {
    "date-parts": [
      [
        2002,
        9,
        3
      ]
    ]
  },
  "reference": [
    {
      "key": "BF6600516_CR1",
      "doi-asserted-by": "publisher",
      "first-page": "105",
      "DOI": "10.1016/S0168-3659(99)00243-6",
      "volume": "65",
      "author": "VR Caiolfa",
      "year": "2000",
      "unstructured": "Caiolfa VR, Zamai M, Fiorino A, Frigerio E, Pellizzoni C, d'Argy R, Ghiglieri A, Castelli MG, Farao M, Pesenti E, Gigli M, Angelucci F, Suarato A (2000) Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 65: 105\u2013119",
      "journal-title": "J Control Release"
    },
    {
      "key": "BF6600516_CR2",
      "doi-asserted-by": "publisher",
      "first-page": "245",
      "DOI": "10.2165/00003088-199733040-00001",
      "volume": "33",
      "author": "GG Chabot",
      "year": "1997",
      "unstructured": "Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245\u2013259",
      "journal-title": "Clin Pharmacokinet"
    },
    {
      "key": "BF6600516_CR3",
      "doi-asserted-by": "publisher",
      "first-page": "407",
      "DOI": "10.1007/s002800050837",
      "volume": "42",
      "author": "CD Conover",
      "year": "1998",
      "unstructured": "Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL (1998) Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethyulene glycol via a glycine linker. Cancer Chemother Pharmacol 42: 407\u2013414",
      "journal-title": "Cancer Chemother Pharmacol"
    },
    {
      "key": "BF6600516_CR4",
      "first-page": "499",
      "volume": "14",
      "author": "CD Conover",
      "year": "1999",
      "unstructured": "Conover CD, Greenwald RB, Pendri A, Sum K (1999) Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-cancer Drug Design 14: 499\u2013506",
      "journal-title": "Anti-cancer Drug Design"
    },
    {
      "key": "BF6600516_CR5",
      "doi-asserted-by": "publisher",
      "first-page": "393",
      "DOI": "10.1007/BF00686188",
      "volume": "36",
      "author": "PJ Houghton",
      "year": "1995",
      "unstructured": "Houghton PJ, Cheshire PJ, Hallman II JD, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumours. Cancer Chemother Pharmacol 36: 393\u2013403",
      "journal-title": "Cancer Chemother Pharmacol"
    },
    {
      "key": "BF6600516_CR6",
      "doi-asserted-by": "publisher",
      "first-page": "89",
      "DOI": "10.1097/00001813-200102000-00002",
      "volume": "12",
      "author": "DF Kehrer",
      "year": "2001",
      "unstructured": "Kehrer DF, Soepenberg O, Loos WJ, Verweij J, Sparreboom A (2001) Modulation of camptothecin analogs in the treatment of cancer: a review. Anti-Cancer Drugs 12: 89\u2013105",
      "journal-title": "Anti-Cancer Drugs"
    },
    {
      "key": "BF6600516_CR7",
      "doi-asserted-by": "publisher",
      "first-page": "98",
      "DOI": "10.1021/jm00105a017",
      "volume": "34",
      "author": "WD Kingsbury",
      "year": "1990",
      "unstructured": "Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher MJ, Caranfa FL, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1990) Synthesis of water soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98\u2013107",
      "journal-title": "J Med Chem"
    },
    {
      "key": "BF6600516_CR8",
      "first-page": "140",
      "volume": "12",
      "author": "RS Lott",
      "year": "1978",
      "unstructured": "Lott RS, Hayton WL (1978) Estimation of creatinine clearance from serum creatinine concentration. Drug Intel Clin Pharm 12: 140\u2013150",
      "journal-title": "Drug Intel Clin Pharm"
    },
    {
      "key": "BF6600516_CR9",
      "doi-asserted-by": "publisher",
      "first-page": "315",
      "DOI": "10.1097/00001813-200104000-00003",
      "volume": "12",
      "author": "JM Meerum Terwogt",
      "year": "2001",
      "unstructured": "Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JHM, Schot M, Mandjes IAM, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH (2001) Phase I clinical study of PNU 166945, a novel water-soluble polymer conjugated prodrug of paclitaxel. Anticancer Drugs 12: 315\u2013323",
      "journal-title": "Anticancer Drugs"
    },
    {
      "key": "BF6600516_CR10",
      "first-page": "95",
      "volume": "56",
      "author": "CG Moertel",
      "year": "1972",
      "unstructured": "Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Reports 56: 95\u2013101",
      "journal-title": "Cancer Chemother Reports"
    },
    {
      "key": "BF6600516_CR11",
      "first-page": "515",
      "volume": "56",
      "author": "FM Muggia",
      "year": "1972",
      "unstructured": "Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Reports 56: 515\u2013521",
      "journal-title": "Cancer Chemother Reports"
    },
    {
      "key": "BF6600516_CR12",
      "unstructured": "NCI (1998) Guidelines for Reporting of Adverse Drug Reactions. National Cancer Institute, Division of Cancer Treatment, Bethesda, MD, USA"
    },
    {
      "key": "BF6600516_CR13",
      "doi-asserted-by": "publisher",
      "first-page": "269",
      "DOI": "10.1016/0163-7258(95)02009-8",
      "volume": "68",
      "author": "LP Rivory",
      "year": "1995",
      "unstructured": "Rivory LP, Robert J (1995) Melcular cellular clinical aspects of the pharmacology of 20 (S)Camptothecin and its derivatives. Pharmac Ther 68: 269\u2013296",
      "journal-title": "Pharmac Ther"
    },
    {
      "key": "BF6600516_CR14",
      "doi-asserted-by": "publisher",
      "first-page": "173",
      "DOI": "10.1016/S0378-4347(01)00391-7",
      "volume": "763",
      "author": "NE Schoemaker",
      "year": "2001",
      "unstructured": "Schoemaker NE, Frigerio E, Fraier D, Schellens JHM, Rosing H, Jansen S, Beijnen JH (2001) High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-Camptothecin) and free camptothecin in human plasma. J Chrom B 763: 173\u2013183",
      "journal-title": "J Chrom B"
    },
    {
      "key": "BF6600516_CR15",
      "first-page": "135",
      "volume": "9",
      "author": "LW Seymour",
      "year": "1992",
      "unstructured": "Seymour LW (1992) Passive tumor targetting of soluble macromolecules drug conjugates. Crit Rev Ther Drug Carrier Sys 9: 135\u2013187",
      "journal-title": "Crit Rev Ther Drug Carrier Sys"
    },
    {
      "key": "BF6600516_CR16",
      "doi-asserted-by": "publisher",
      "first-page": "1138",
      "DOI": "10.1093/jnci/89.15.1138",
      "volume": "89",
      "author": "R Simon",
      "year": "1997",
      "unstructured": "Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accellerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138\u20131147",
      "journal-title": "J Natl Cancer Inst"
    },
    {
      "key": "BF6600516_CR17",
      "doi-asserted-by": "publisher",
      "first-page": "271",
      "DOI": "10.1093/jnci/85.4.271",
      "volume": "85",
      "author": "WJ Slichenmyer",
      "year": "1993",
      "unstructured": "Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271\u2013291",
      "journal-title": "J Natl Cancer Inst"
    },
    {
      "key": "BF6600516_CR18",
      "first-page": "195",
      "volume": "37",
      "author": "SL Traub",
      "year": "1980",
      "unstructured": "Traub SL, Johnson CE (1980) Comparison of methods of estimating creatinine clearance in children. Am J Hosp Pharm 37: 195\u2013201",
      "journal-title": "Am J Hosp Pharm"
    },
    {
      "key": "BF6600516_CR19",
      "first-page": "83",
      "volume": "5",
      "author": "PA Vasey",
      "year": "1999",
      "unstructured": "Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E, Cassidy J (1999) Phase I clinical and pharmacodynamic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents\u2013drug-polymer conjugates. Clin Cancer Res 5: 83\u201394",
      "journal-title": "Clin Cancer Res"
    },
    {
      "key": "BF6600516_CR20",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "DOI": "10.1111/j.1749-6632.1996.tb26371.x",
      "volume": "803",
      "author": "ME Wall",
      "year": "1996",
      "unstructured": "Wall ME, Wani MC (1996) Camptothecin Discovery to clinic. Ann NY Ac Sc 803: 1\u201312",
      "journal-title": "Ann NY Ac Sc"
    },
    {
      "key": "BF6600516_CR21",
      "unstructured": "WHO (1979) WHO handbook for Reporting Results of Cancer Treatment World Health Organization, Geneva, Switzerland"
    }
  ],
  "container-title": "British Journal of Cancer",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "http://www.nature.com/articles/6600516.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/6600516",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/6600516.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ],
    "date-time": "2023-05-18T12:44:40Z",
    "timestamp": 1684413880000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/6600516"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2002,
        9
      ]
    ]
  },
  "references-count": 21,
  "journal-issue": {
    "issue": "6",
    "published-print": {
      "date-parts": [
        [
          2002,
          9
        ]
      ]
    }
  },
  "alternative-id": [
    "BF6600516"
  ],
  "URL": "http://dx.doi.org/10.1038/sj.bjc.6600516",
  "relation": {},
  "ISSN": [
    "0007-0920",
    "1532-1827"
  ],
  "subject": [],
  "container-title-short": "Br J Cancer",
  "published": {
    "date-parts": [
      [
        2002,
        9
      ]
    ]
  }
}